UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1135-13
Program Prior Authorization/Notification
Medication Syprine® (trientine hydrochloride)*, Trientine hydrochloride
P&T Approval Date 7/2014, 7/2015, 6/2016, 6/2017, 6/2018, 6/2019, 6/2020, 6/2021,
6/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Backgrounda:
Syprine (trientine hydrochloride) and trientine hydrochloride are indicated for the treatment of
patients with Wilson’s disease who are intolerant of penicillamine. Syprine and trientine
hydrochloride cannot be considered interchangeable with penicillamine. Syprine and trientine
hydrochloride should be used when continued treatment with penicillamine is no longer possible
because of intolerable or life endangering side effects.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Syprine* or trientine hydrochloride will be approved based on both of the following
criteria:
a. Diagnosis of Wilson’s disease (i.e., hepatolenticular degeneration)
-AND-
b. History of intolerance, failure or contraindication to penicillamine
Authorization will be issued for 12 months.
B. Reauthorization
1. Syprine* or trientine hydrochloride will be approved based on the following
criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Syprine® (trientine hydrochloride) is typically excluded from coverage. Tried/Failed criteria may be
in place. Please refer to plan specifics to determine exclusion status.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Syprine [package insert]. Bridgewater, NJ: Bausch Health US, LLC; September 2020.
2. Trientine hydrochloride [package insert]. Parsippany, NJ: Teva Pharmaceuticals; January
2022.
Program Prior Authorization/Notification – Syprine* (trientine hydrochloride), Trientine
hydrochloride
Change Control
7/2014 New program.
9/2014 Administrative change – Tried/Failed exemption for State of New Jersey
removed.
7/2015 Annual Review. References updated. Added notation that Cuprimine is now
excluded from coverage.
6/2016 Annual Review. Changed initial authorization to 12 months and added
reauthorization for 24 months. Updated background, formatting and
references.
6/2017 Annual review. Updated references.
6/2018 Annual review. No changes.
6/2019 Annual review. No changes.
6/2020 Annual review. No changes.
6/2021 Annual review with no changes to clinical criteria. Updated references.
6/2022 Annual review. Cuprimine and Depen removed as examples from Coverage
Criteria as they are typically excluded from coverage and generic penicillamine
is available. Changed reauthorization to 12 months to align with
reauthorization period for other pharmacy programs.
6/2023 Annual review. Added generic trientine hydrochloride to program and noted
that Brand Syprine is typically excluded from coverage for most plans.
Updated references and added state mandate footnote.
6/2024 Annual review with no changes to criteria.
6/2025 Annual review with no changes to criteria. Updated formatting.
© 2025 UnitedHealthcare Services, Inc.
2